NICE has turned the Alzheimer's drug fight into a carer-economics fight. Alzheimer Europe reported that NICE will reconsider lecanemab and donanemab after appeal panels upheld key grounds from Eisai and Lilly, including infusion-cost timing and the treatment of carer utilities. [1] The paper's Friday article on Cochrane versus Kisunla and the June NICE clock treated June 10 as the operative artifact. Saturday's addition is what the appeal says the artifact must count.

The donanemab appeal decision states that the panel considered whether NICE's manual includes the health of a person as including both a patient and a carer. [2] It also upheld points tied to NHS England infusion-cost estimates and unpaid care costs. [2] The lecanemab appeal decision similarly turned on fairness, consultation time, and how evidence was weighed. [3] This is not only a drug-price dispute. It is a model-design dispute over whose burden enters the cost-effectiveness calculation.

Alzheimer Europe's summary is blunt: for lecanemab, the panel found that the committee's assessment of carer utility values was unreasonable given evidence that EQ-5D underestimated the impact of Alzheimer's on carers; for donanemab, the panel upheld equivalent findings and added unpaid-care-cost concerns. [1] Alzheimer's Society welcomed NICE's decision to look again, especially at the significant impact of dementia on unpaid carers. [4]

MSM tends to phrase the dispute as whether expensive anti-amyloid drugs deliver benefits large enough for NHS coverage. X and patient-advocacy spaces are reading the narrower accounting question: if a medicine buys months of slower decline, who receives those months, and who supplies the unpaid labor that makes them livable. The second question is less tidy and more humane.

NICE may still reject the drugs. But after the appeals, rejection has to pass through carers, infusion logistics, and unpaid work, not just through a price tag and a trial endpoint.

-- NORA WHITFIELD, Chicago